News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NanoViricides, Inc. (NNVC.PK) Announces that DengueCide™ Has Received Orphan Drug Designation From the European Medicines Agency


11/11/2013 9:02:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC) (the "Company") announced today that the European Medicines Agency (EMA), has awarded orphan drug designation to DengueCide™, the Company’s drug candidate for the treatment of dengue and dengue hemorrhagic fever. Dengue Fever is a mosquito-borne disease that, according to the WHO, affects approximately 400 million people per year. Dengue Hemorrhagic Fever, a subset of the disease that can occur after reinfection with another strain of the same virus, has a case fatality rate of up to 20%.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES